Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

CRDF Stock  USD 2.61  0.07  2.76%   
Roughly 55% of Cardiff Oncology's stockholders are presently thinking to get in. The analysis of overall sentiment of trading Cardiff Oncology stock suggests that some investors are interested at this time. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
  
- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 -- Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier th

Read at finance.yahoo.com
Yahoo News
  

Cardiff Oncology Fundamental Analysis

We analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Cardiff Oncology is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Cardiff Oncology Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cardiff Oncology stock to make a market-neutral strategy. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics with similar companies.

Peers

Cardiff Oncology Related Equities

CUECue Biopharma   11.93   
0%
100.0%
LYRALyra Therapeutics   10.53   
0%
88.0%
RVPHReviva Pharmaceuticals   8.77   
0%
73.0%
NLSPNLS Pharmaceutics   3.36   
0%
28.0%
LTRNLantern Pharma   3.22   
0%
26.0%
RNAZTranscode Therapeutics   2.94   
0%
24.0%
CGEMCullinan Oncology   2.75   
0%
23.0%
PDSBPDS Biotechnology   1.86   
0%
15.0%
KODKodiak Sciences   1.83   
0%
15.0%
BOLTBolt Biotherapeutics   1.59   
0%
13.0%
AUTLAutolus Therapeutics   1.53   
0%
12.0%
DAWNDay One   1.53   
0%
12.0%
MREOMereo BioPharma   1.40   
0%
11.0%
CGTXCognition Therapeutics   2.44   
20.0%
0%
INABIn8bio   3.23   
27.0%
0%
SLSSellas Life   3.42   
28.0%
0%
RVPHWReviva Pharmaceuticals   4.35   
36.0%
0%

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities